UY30974A1 - Metodo para tratar el dolor mediado por los receptores de cb2 (ii) - Google Patents

Metodo para tratar el dolor mediado por los receptores de cb2 (ii)

Info

Publication number
UY30974A1
UY30974A1 UY30974A UY30974A UY30974A1 UY 30974 A1 UY30974 A1 UY 30974A1 UY 30974 A UY30974 A UY 30974A UY 30974 A UY30974 A UY 30974A UY 30974 A1 UY30974 A1 UY 30974A1
Authority
UY
Uruguay
Prior art keywords
receivers
treating pain
pain mediated
subject
mediated
Prior art date
Application number
UY30974A
Other languages
English (en)
Inventor
Mingde Xia
Kevin Paul Pavlick
Mark J Macielag
Christopher Flores
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39766330&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY30974(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of UY30974A1 publication Critical patent/UY30974A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se refiere a un método para tratar, aliviar o evitar el dolor mediado por los receptores CB2 en un sujeto que lo necesita, cuyo método comprende administrar al sujeto una cantidad eficaz de un compuesto de la formula (i): o una forma del mismo, en el cual X1R1, X2R2, X3R3, X4R4, y X5R5 son como se definieron en la presente.
UY30974A 2007-03-21 2008-03-19 Metodo para tratar el dolor mediado por los receptores de cb2 (ii) UY30974A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89601707P 2007-03-21 2007-03-21

Publications (1)

Publication Number Publication Date
UY30974A1 true UY30974A1 (es) 2008-09-30

Family

ID=39766330

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30974A UY30974A1 (es) 2007-03-21 2008-03-19 Metodo para tratar el dolor mediado por los receptores de cb2 (ii)

Country Status (13)

Country Link
EP (1) EP2139327A4 (es)
JP (1) JP2010522182A (es)
KR (1) KR20090120500A (es)
CN (1) CN101677555A (es)
AR (1) AR065801A1 (es)
AU (1) AU2008229265A1 (es)
CA (1) CA2681384A1 (es)
CL (1) CL2008000817A1 (es)
MX (1) MX2009010164A (es)
PE (1) PE20090551A1 (es)
TW (1) TW200904414A (es)
UY (1) UY30974A1 (es)
WO (1) WO2008115672A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012090179A2 (en) 2010-12-30 2012-07-05 Lupin Limited Isoquinoline derivatives as cannabinoid receptor modulators
WO2012090177A2 (en) 2010-12-30 2012-07-05 Lupin Limited Cannabinoid receptor modulators
IN2014MN00226A (es) 2011-07-05 2015-09-25 Lupin Ltd

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200605383B (en) * 2003-12-29 2008-06-25 Sepracor Inc Pyrrole and pyrazole daao inhibitors
US7452997B2 (en) * 2004-03-24 2008-11-18 Janssen Pharmaceutica, N.V. Tetrahydro-indazole cannabinoid modulators
FR2875230A1 (fr) * 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
ES2340201T3 (es) * 2005-09-23 2010-05-31 Janssen Pharmaceutica Nv Moduladores de hexahidro-ciclooctilpirazol cannabinoides.
US7825151B2 (en) * 2005-09-23 2010-11-02 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators

Also Published As

Publication number Publication date
PE20090551A1 (es) 2009-05-16
CA2681384A1 (en) 2008-09-25
KR20090120500A (ko) 2009-11-24
WO2008115672A1 (en) 2008-09-25
AR065801A1 (es) 2009-07-01
CN101677555A (zh) 2010-03-24
JP2010522182A (ja) 2010-07-01
CL2008000817A1 (es) 2008-09-26
EP2139327A1 (en) 2010-01-06
TW200904414A (en) 2009-02-01
MX2009010164A (es) 2009-10-12
EP2139327A4 (en) 2011-06-15
AU2008229265A1 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
PA8841901A1 (es) Compuestos orgánicos
CL2019003798A1 (es) Métodos para tratar la enfermedad de huntington.
GT201400102A (es) 4-fenil-piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1
CR20110046A (es) Amidofenoxiindazoles utiles como inhibidores de c-met
UY32110A (es) Inhibidores de aminopirimidina de los receptores de histamina para el tratamiento de una enfermedad
UY32111A (es) Inhibidores heterociclicos de los receptores de histamina para el tratamiento de una enfermedad
CO6341577A2 (es) Oligonucleotidos antisentido dirigidos contra el factor de crecimiento del tejido conectivo y usos de los mismos
CO6341558A2 (es) Antagonistas del recepptor de nmda para el tratamiento de trastornos neuropsiquiatricos
AR091837A1 (es) Compuestos para inmunoterapia dirigida
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
ECSP10010518A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
NI201500094A (es) Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y métodos de tratamiento con los mismos.
CL2015001389A1 (es) Composiciones y compuestos antihelmínticos y métodos para usarlos.
EA201290919A1 (ru) Индазольные соединения и их применение
UY33627A (es) Compuestos para tratar enfermedades neurodegenerativas
CO6511220A2 (es) Quinazolinas como inhibidores de los canales iónicos de potasio
ECSP12011815A (es) Métodos sintéticos para compuestos espiro-oxoindol
UY33271A (es) Inhibidores heterocíclicos de los receptores de histamina para el tratamiento de una enfermedad
PE20210949A1 (es) Anticuerpos anti-fgfr2iiib afucosilados
GT201200004A (es) Imidazoles fusionados y composiciones que los contienen para el tratamiento de enfermedades parasitarias, como por ejemplo malaria
PA8850801A1 (es) Compuestos útiles para inhibir chk1
CO6351779A2 (es) Inhibidores de molecula pequeña de la activacion n-terminal del receptor de androgenos
UA107562C2 (uk) Спосіб лікування псоріазу
UY31162A1 (es) Espiroindolinas como moduladores de receptores de quimioquinas
UY30974A1 (es) Metodo para tratar el dolor mediado por los receptores de cb2 (ii)